HCC-话题@MedSci

#HCC#

114篇内容 | 2450人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1259500, encodeId=022112595009c, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=J Hepatol：接受DAA治疗的HCV晚期患者，新发HCC比率不高，可能是先前显微、未发现的肿瘤, objectType=article, longId=133476, objectId=28c81334e64c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28c81334e64c, replyNumber=0, likeNumber=34, createdTime=2018-03-27, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28c81334e64c, moduleTitle=J Hepatol：接受DAA治疗的HCV晚期患者，新发HCC比率不高，可能是先前显微、未发现的肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28c81334e64c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259499, encodeId=05f51259499b6, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=JCO：局部晚期HCC患者是否推荐放射性栓塞治疗, objectType=article, longId=132144, objectId=b8ed13214436, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8ed13214436, replyNumber=0, likeNumber=37, createdTime=2018-03-13, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8ed13214436, moduleTitle=JCO：局部晚期HCC患者是否推荐放射性栓塞治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8ed13214436)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259498, encodeId=4d081259498e2, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Aliment Pharmacol Ther：常规监测的CHB患者HCC检测失败的预测因素, objectType=article, longId=131795, objectId=ac91131e9558, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac91131e9558, replyNumber=0, likeNumber=43, createdTime=2018-03-09, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac91131e9558, moduleTitle=Aliment Pharmacol Ther：常规监测的CHB患者HCC检测失败的预测因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ac91131e9558)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259497, encodeId=2851125949e0a, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Radiology：DEB-TACE评估肿瘤生物学及肝细胞肝癌（HCC）5年移植复发率, objectType=article, longId=130176, objectId=d4551301e6b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4551301e6b1, replyNumber=0, likeNumber=33, createdTime=2018-02-20, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4551301e6b1, moduleTitle=Radiology：DEB-TACE评估肿瘤生物学及肝细胞肝癌（HCC）5年移植复发率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4551301e6b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259496, encodeId=f38612594961c, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=J HEPATOL:LI-RADS标准对小于3 cm的HCC的非侵入性诊断价值并不优于AASLD标准, objectType=article, longId=127513, objectId=dc2312e5139d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc2312e5139d, replyNumber=0, likeNumber=38, createdTime=2018-01-25, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc2312e5139d, moduleTitle=J HEPATOL:LI-RADS标准对小于3 cm的HCC的非侵入性诊断价值并不优于AASLD标准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc2312e5139d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259495, encodeId=f6d8125949500, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Liver Int：高γ-球蛋白血症是代偿性肝硬化患者疾病进展、HCC发生和死亡的预测因素, objectType=article, longId=123104, objectId=4df31231048e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4df31231048e, replyNumber=0, likeNumber=38, createdTime=2017-12-13, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4df31231048e, moduleTitle=Liver Int：高γ-球蛋白血症是代偿性肝硬化患者疾病进展、HCC发生和死亡的预测因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4df31231048e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259494, encodeId=ca4f12594940a, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=PHCC第三届国际初级卫生保健会议重点强调推进初级卫生保健, objectType=article, longId=122746, objectId=4bb3122e4605, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4bb3122e4605, replyNumber=0, likeNumber=36, createdTime=2017-12-10, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4bb3122e4605, moduleTitle=PHCC第三届国际初级卫生保健会议重点强调推进初级卫生保健, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4bb3122e4605)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259493, encodeId=7c7b12594930e, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=J Viral Hepat：国际间比较：在DAA治疗之前，HCV患者HCC发生率较高和存活率较低, objectType=article, longId=122213, objectId=31e91222138b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=31e91222138b, replyNumber=0, likeNumber=29, createdTime=2017-12-05, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=31e91222138b, moduleTitle=J Viral Hepat：国际间比较：在DAA治疗之前，HCV患者HCC发生率较高和存活率较低, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=31e91222138b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259492, encodeId=80da125949264, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=J Viral Hepat：HBeAg(+)高病毒载量患者，抗病毒治疗期间病毒抑制延迟增加了HCC发生率, objectType=article, longId=122123, objectId=30d7122123c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=30d7122123c6, replyNumber=0, likeNumber=40, createdTime=2017-12-04, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=30d7122123c6, moduleTitle=J Viral Hepat：HBeAg(+)高病毒载量患者，抗病毒治疗期间病毒抑制延迟增加了HCC发生率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=30d7122123c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259491, encodeId=09281259491c9, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=J Hepatol:使用和未使用IFN的慢性丙肝患者HCC早期发生和复发风险竟然相似！, objectType=article, longId=121695, objectId=c56112169563, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c56112169563, replyNumber=0, likeNumber=28, createdTime=2017-11-30, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c56112169563, moduleTitle=J Hepatol:使用和未使用IFN的慢性丙肝患者HCC早期发生和复发风险竟然相似！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c56112169563)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259490, encodeId=a46b1259490ff, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=AASLD特约点评 | 赵明教授：Checkmate-040 研究——Nivolumab治疗晚期HCC的数据更新, objectType=article, longId=121557, objectId=f7f212155e0e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f7f212155e0e, replyNumber=0, likeNumber=33, createdTime=2017-11-29, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f7f212155e0e, moduleTitle=AASLD特约点评 | 赵明教授：Checkmate-040 研究——Nivolumab治疗晚期HCC的数据更新, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f7f212155e0e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259489, encodeId=0c6612594897f, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Hepatology：抗血小板治疗会降低慢性乙肝患者HCC风险吗？, objectType=article, longId=120963, objectId=773d12096392, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=773d12096392, replyNumber=0, likeNumber=24, createdTime=2017-11-23, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=773d12096392, moduleTitle=Hepatology：抗血小板治疗会降低慢性乙肝患者HCC风险吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=773d12096392)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259488, encodeId=a3b712594883d, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Sci Rep：研究进一步揭示HCC耐药性的潜在机制, objectType=article, longId=113694, objectId=c1a511369488, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1a511369488, replyNumber=0, likeNumber=34, createdTime=2017-09-23, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1a511369488, moduleTitle=Sci Rep：研究进一步揭示HCC耐药性的潜在机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1a511369488)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259487, encodeId=07f3125948ee6, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Hepatology：HCC患者接受索拉非尼治疗获得完全应答及其与皮肤学反应的关系, objectType=article, longId=112896, objectId=2e4311289681, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e4311289681, replyNumber=0, likeNumber=32, createdTime=2017-09-16, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e4311289681, moduleTitle=Hepatology：HCC患者接受索拉非尼治疗获得完全应答及其与皮肤学反应的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e4311289681)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259486, encodeId=2392125948641, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Lancet 重磅！瑞格菲尼在治疗晚期HCC的3期临床试验获得成功, objectType=article, longId=87963, objectId=6f318e96342, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f318e96342, replyNumber=0, likeNumber=0, createdTime=2017-01-24, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f318e96342, moduleTitle=Lancet 重磅！瑞格菲尼在治疗晚期HCC的3期临床试验获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f318e96342)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259485, encodeId=fdc71259485fe, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Ann Surg：HCC术后复发的原因在此！, objectType=article, longId=87882, objectId=dbf18e8822b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbf18e8822b, replyNumber=0, likeNumber=44, createdTime=2017-01-22, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbf18e8822b, moduleTitle=Ann Surg：HCC术后复发的原因在此！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dbf18e8822b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259484, encodeId=08e11259484e5, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Sci Rep：周伟平等人发现HCC转移新机制, objectType=article, longId=83664, objectId=f72d836640a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f72d836640a, replyNumber=0, likeNumber=27, createdTime=2016-12-08, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f72d836640a, moduleTitle=Sci Rep：周伟平等人发现HCC转移新机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f72d836640a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259483, encodeId=3ed412594831a, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Hepatology：核苷（酸）类似物治疗可降低HBV相关性HCC的复发率, objectType=article, longId=69264, objectId=6ce26926482, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ce26926482, replyNumber=0, likeNumber=39, createdTime=2016-05-27, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ce26926482, moduleTitle=Hepatology：核苷（酸）类似物治疗可降低HBV相关性HCC的复发率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ce26926482)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259482, encodeId=5cac12594828e, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=存在HCC史的患者近1/3在接受DAA治疗后复发, objectType=article, longId=66522, objectId=41656652216, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41656652216, replyNumber=0, likeNumber=50, createdTime=2016-04-16, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41656652216, moduleTitle=存在HCC史的患者近1/3在接受DAA治疗后复发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41656652216)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259481, encodeId=8e961259481c4, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Hepatology：系统回顾基于碘油的TACE治疗HCC的有效性和安全性, objectType=article, longId=64422, objectId=1b81644224a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b81644224a, replyNumber=0, likeNumber=36, createdTime=2016-03-09, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b81644224a, moduleTitle=Hepatology：系统回顾基于碘油的TACE治疗HCC的有效性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b81644224a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

HCC

2020-05-29

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

J Hepatol：接受DAA治疗的HCV晚期患者，新发HCC比率不高，可能是先前显微、未发现的肿瘤

2018-03-27

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

JCO：局部晚期HCC患者是否推荐放射性栓塞治疗

2018-03-13

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

Aliment Pharmacol Ther：常规监测的CHB患者HCC检测失败的预测因素

2018-03-09

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

Radiology：DEB-TACE评估肿瘤生物学及肝细胞肝癌（HCC）5年移植复发率

2018-02-20

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

J HEPATOL:LI-RADS标准对小于3 cm的HCC的非侵入性诊断价值并不优于AASLD标准

2018-01-25

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

Liver Int：高γ-球蛋白血症是代偿性肝硬化患者疾病进展、HCC发生和死亡的预测因素

2017-12-13

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

PHCC第三届国际初级卫生保健会议重点强调推进初级卫生保健

2017-12-10

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

J Viral Hepat：国际间比较：在DAA治疗之前，HCV患者HCC发生率较高和存活率较低

2017-12-05

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

J Viral Hepat：HBeAg(+)高病毒载量患者，抗病毒治疗期间病毒抑制延迟增加了HCC发生率

2017-12-04

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

J Hepatol:使用和未使用IFN的慢性丙肝患者HCC早期发生和复发风险竟然相似！

2017-11-30

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

AASLD特约点评 | 赵明教授：Checkmate-040 研究——Nivolumab治疗晚期HCC的数据更新

2017-11-29

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

Hepatology：抗血小板治疗会降低慢性乙肝患者HCC风险吗？

2017-11-23

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

Sci Rep：研究进一步揭示HCC耐药性的潜在机制

2017-09-23

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

Hepatology：HCC患者接受索拉非尼治疗获得完全应答及其与皮肤学反应的关系

2017-09-16

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

Lancet 重磅！瑞格菲尼在治疗晚期HCC的3期临床试验获得成功

2017-01-24

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

Ann Surg：HCC术后复发的原因在此！

2017-01-22

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

Sci Rep：周伟平等人发现HCC转移新机制

2016-12-08

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

Hepatology：核苷（酸）类似物治疗可降低HBV相关性HCC的复发率

2016-05-27

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

存在HCC史的患者近1/3在接受DAA治疗后复发

2016-04-16

智智灵药 (审核中...)

前往app查看评论内容

#HCC#

Hepatology：系统回顾基于碘油的TACE治疗HCC的有效性和安全性

2016-03-09

科室
- - 订阅+
  - 更多科室
工具
服务